Blood-Brain Barrier Engineering For Neurotherapeutic Delivery

Blood-brain barrier engineering for neurotherapeutic delivery focuses on designing drug delivery systems that cross or transiently modulate the BBB to move therapeutic molecules into the central nervous system. The BBB regulates molecular movement between blood and neural tissue, maintains brain homeostasis, and blocks many diagnostic and therapeutic agents from entering brain parenchyma. This delivery barrier remains central to neurodegenerative disease, ischemic injury, brain tumors, and CNS infection research because even a damaged BBB can still restrict effective brain drug delivery^[1][2].

Current strategies exploit endogenous transport routes or externally controlled BBB opening. Transferrin- and transferrin-receptor-antibody-modified human serum albumin nanoparticles transported loperamide across the BBB in mice, supporting receptor-mediated delivery through transferrin-linked targeting. Insulin receptor-targeted albumin nanoparticles also transported loperamide across the BBB, and pretreatment with an anti-insulin receptor antibody inhibited this transport. Lactoferrin-conjugated PEG-coated magnetic nanoparticles crossed BBB models by receptor-mediated transcytosis through lactoferrin receptors on cerebral endothelial cells. These studies define receptor-mediated transcytosis as a major engineering route for brain-targeted nanoparticles^[2][3][4].

Focused ultrasound adds a spatially controlled delivery route by locally and transiently opening the BBB with microbubbles. Reviews describe focused ultrasound plus microbubbles as a method for delivering antibodies, growth factors, and nanomedicine formulations into selected brain regions. MRI-visible albumin nanoclusters were deposited into target rat brain regions through focused ultrasound-facilitated BBB opening, and a second ultrasound treatment triggered payload release. Long-circulating biodegradable nanoparticles combined with focused ultrasound delivered plasmid DNA, mRNA, and CRISPR-associated payloads to astrocytes and neurons in the treated brain region, supporting systemic nucleic acid delivery and site-specific genome editing^[5][6][7].

The main research gap is controlled translation: delivery systems must balance BBB penetration, regional precision, payload stability, brain distribution, safety, and reproducibility. Nanoparticle composition, ligand density, receptor expression, circulation time, serum stability, ultrasound parameters, microbubble behavior, and disease-specific BBB changes all influence delivery performance. Future studies should compare receptor-mediated transcytosis, focused ultrasound opening, and hybrid nanoparticle approaches using shared endpoints such as brain accumulation, cell-type tropism, payload release, pharmacodynamic activity, vascular safety, and neurological tolerability. These priorities can guide neurotherapeutic delivery for Alzheimer’s disease, Parkinson’s disease, stroke, glioblastoma, CNS infection, and gene-editing applications^[1][5][6][7].